Scientific Program - PDMD
|
Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here
|
| Adamantiades-Behçet's disease | The Brain and Mind in Greek Philosophy | Contursi Kindred |
Dementia |
| Epilepsy |
Headache | Multiple Sclerosis | Neuroimmunology |
|
Parkinson's disease &
Movement disorders |
Rehabilitation / Sleep | Stroke |
| Section Heads: Maria Stamelou, Greece & Heinz Reichmann, Germany |
|
|||
| 15:45-16:15 |
PDMD LECTURE
|
||
| The new antiparkinson drugs: Are they really better? | |||
| Laszlo Vecsei, Hungary | |||
|
|||
| 8:00-10:00 |
DEMENTIA WITH LEWY BODIES (DLB)
|
||
| Chairs: Dimitrios Anastasopoulos, Greece; Dmitri Pokhabov, Russia | |||
| 8:00-9:00 | Proposition: DLB and dementia of PD are the same disorder | ||
| Capsule: |
Most PD patients develop ultimately dementia, while in some patients a-synuclein pathology involves cortical regions before the manifestation of parkinsonism. Do DLB and PDD represent different phenotypic manifestations of the same disease, or not?
|
||
| 8:00-8:10 | Host: K. Jellinger, Austria | ||
| 8:10-8:25 |
Pro: Irena Rektorova, Czech Republic
|
||
| 8:25-8:40 | Con: Albert Ludolph, Germany | ||
| 8:40-9:00 | Discussion and rebuttals | ||
| 9:00-10:00 |
Debate: DLB can be confidently diagnosed in patients who only have cognitive decline and REM-sleep behaviour disorder (RSBD).
|
||
| Capsule: | RSBD is present usually in alpha-synucleinopathies, however, it has also been described in Alzheimer’s disease and other dementias. In a patient with cognitive dysfunction and RSBD is DLB the most likely diagnosis? | ||
| 9:00-9:10 | Host:Sokratis Papageorgiou, Greece | ||
| 9:10-9:25 | Pro: Babak Tousi, USA | ||
| 9:25-9:40 | Con: Paraskevi Sakka, Greece | ||
| 9:40-10:00 |
Discussion and rebuttals | ||
| 10:00-10:15 |
Coffee Break | ||
| 10:15-12:10 | PD BIOMARKERS | ||
| Chairs: Pantelis Stathis, Greece; Viktoriia Gryb, Ukraine | |||
| 10:15-11:10 | Debate: Is alpha-synuclein a useful biomarker in PD? | ||
| Capsule: | Currently there is no biomarker for PD and this is urgently needed. There is controversial evidence as to whether alpha-synuclein, the pathological substrate of Lewy bodies, could serve as a valid biomarker in PD. | ||
| 10:15-10:25 |
Host: Serena Hung, USA
|
||
| 10:25-10:40 | Yes: Albert Ludolph, Germany | ||
| 10:40-10:55 | No: Bogdan Popescu, Romania | ||
| 10:55-11:10 | Discussion and rebuttals | ||
| 11:10-12:10 |
Debate: Is imaging very useful in the diagnosis of parkinsonism? | ||
| Capsule: |
Brain Imaging may have some value in the diagnosis and management of parkinsonism, but there remains uncertainty regarding the generalizability of using MRI and dopamine imaging studies. Moreover, the sensitivity and specificity of imaging in differentiating between different parkinsonian disorders is controversial. Should imaging be routinely applied and is it really useful in the diagnosis of parkinsonism?
|
||
| 11:10-11:20 |
Host: Stuart Isaacson, USA
|
||
| 11:20-11:35 | Yes: Marios Politis, UK | ||
| 11:35-11:50 | No: Maria Stamelou, Greece | ||
| 11:50-12:10 | Discussion and rebuttals | ||
| 15:05-17:00 |
PATHOGENESIS
|
||
| Chairs: TBA; Cristian Falup-Pecurariu, Romania | |||
| 15:05-16:00 | Proposition: The etiology of PD is predominantly genetic | ||
| Capsule: | Increasing evidence supports the importance of genetic risk factors in the pathogenesis of PD. On the other hand, still, in the majority of the patients the disease is considered sporadic. Could genetics be the most predominant factor in the etiology of PD? | ||
| 15:05-15:15 |
Host: Paolo Barone, Italy
|
||
| 15:15-15:30 | Pro: Georgia Xiromerisiou, Greece | ||
| 15:30-15:45 | No: Heinz Reichmann, Germany | ||
| 15:45-16:00 |
Discussion and rebuttals | ||
| 16:00-17:00 | Proposition: The gastrointestinal system is important in the pathogenesis of PD | ||
| Capsule: | There is some evidence that PD could be initiated in the gut, and that the presence of alpha-synuclein aggregates or Lewy bodies in the enteric nervous system represents one of the earliest stages of the disease. On the other hand, there is evidence that does not fit to this hypothesis. Does PD start in the gut? | ||
| 16:00-16:15 |
Host: Maria Stamelou, Greece
|
||
| 16:15-16:30 | Pro: Bogdan Popescu, Romania | ||
| 16:30-16:45 | Con: Paolo Barone, Italy | ||
| 16:45-17:00 | Discussion and rebuttals | ||
| 17:00-17:15 | Coffee Break | |
| 17:15-18:00 |
PARKINSON'S DISEASE THERAPY
|
|
| Chairs: Zinovia Kefalopoulou, Greece; Ilana Schlesinger, Israel | ||
| 17:15-18:00 | Debate: Is there enough evidence for the use of antipsychotics in PD psychosis? | |
| Capsule: |
PD psychosis is a common problem in clinical practice. A variety if antipsychotics and recent new ones have been widely applied in clinical practice. How evidence-based are these antipsychotic treatments for PD?
|
|
| 17:15-17:25 |
Host: Babak Tousi, USA
|
|
| 17:25-17:40 |
Yes: Stuart Isaacson, USA
|
|
| 17:40-17:55 | No: Heinz Reichmann, Germany |
|
| 17:55-18:00 |
Discussion and rebuttals | |
|
|||
| 7:00-7:55 | E-Poster Presentations (Epilepsy, Alzheimers, Rehabilitation, Sleep, & Miscellaneous) | ||
|
8:00-9:00
|
GWAS IN PARKINSON’S DISEASE (PD)
|
||
| Chairs: K. I. Tudor, Croatia; Lefkos Middleton, UK | |||
| 8:00-9:00 |
Debate: Further GWAS studies in PD are a waste of time and money
|
||
| Capsule: | The last decade saw an explosion of GWAS studies in PD, involving thousands of patients and controls. Besides the information derived from previous studies on the role of Alpha Synuclein and genes implicated in familial forms, GWAS has had no significant impact on our understanding of the biological mechanisms underpinning the aetiology of Parkinson’s disease. |
||
| 8:00-8:10 | Host: Ilana Schlesinger, Israel |
||
| 8:10-8:25 | Yes: Evangelos Evangelou, UK (TBC) |
||
| 8:25-8:40 |
No: Pierandrea Muglia, Belgium |
||
| 8:40-9:00 | Discussion and rebuttals |
||
